KRT88P and hepatitis B virus infection: After autologous HSCT, hepatitis B developed in anti-HBc patients later (6–52 months, average 19 months) than in overt carriers (average 2–3 months) and none of the patients described died of hepatitis B (in 7 cases during therapy with lamivudine, started at the time of the clinical relapse).